tiprankstipranks
Crispr Therapeutics AG (GB:0VRQ)
LSE:0VRQ
UK Market

Crispr Therapeutics AG Stock Analysis & Ratings

GB:0VRQ Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$53.39
VolumeN/A
Average Volume (3M)875.00
Market Cap$4.14B
P/E Ratio14.8
Beta0.82
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score9
EPS (TTM)3.60


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0VRQ FAQ

What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Crispr Therapeutics AG’s market cap?
    Crispr Therapeutics AG’s market cap is $4.14B.
      What is Crispr Therapeutics AG’s price target?
      The average price target for Crispr Therapeutics AG is $95.15. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $150.00 ,the lowest forecast is $52.00. The average price target represents 78.22% Increase from the current price of $53.39.
        What do analysts say about Crispr Therapeutics AG?
        Crispr Therapeutics AG’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
          When is Crispr Therapeutics AG’s upcoming earnings report date?
          Crispr Therapeutics AG’s upcoming earnings report date is Aug 10, 2022 which is in 84 days.
            How were Crispr Therapeutics AG’s earnings last quarter?
            Crispr Therapeutics AG released its earnings results on May 11, 2022. The company reported -$2.32 earnings per share for the quarter, missing the consensus estimate of -$1.939 by -$0.381.
              Is Crispr Therapeutics AG overvalued?
              According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
                Does Crispr Therapeutics AG pay dividends?
                Crispr Therapeutics AG does not currently pay dividends.
                What is Crispr Therapeutics AG’s EPS estimate?
                Crispr Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Crispr Therapeutics AG have?
                Crispr Therapeutics AG has 77,460,000 shares outstanding.
                  What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
                  Crispr Therapeutics AG reported an EPS of -$2.32 in its last earnings report, missing expectations of -$1.939. Following the earnings report the stock price went down -8.092%.
                    Which hedge fund is a major shareholder of Crispr Therapeutics AG?
                    Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 590M.

                      ---

                      Crispr Therapeutics AG Stock Analysis

                      Smart Score
                      9
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $95.15
                      ▲(78.22% Upside)
                      Moderate Buy
                      The Crispr Therapeutics AG stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Crispr Therapeutics AG

                      CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Editas Medicine
                      Intellia Therapeutics
                      Sangamo Biosciences
                      Bluebird Bio
                      Invitae

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis